Sign In
Last checked at 
5 Mar 2009 15:20
ļ»æ
Physiomics plc
The Magdalen Centre
TheĀ OxfordĀ ScienceĀ ParkRobert Robinson AvenueOxford
OX4 4GAUK
Tel 01865 784980
Fax 08701 671931
5 March 2009
Physiomics plc ("Physiomics" or "the Company")
Holdings in Company
The Company has been informedĀ todayĀ that following a sale ofĀ 17,800,000Ā Ordinary Shares of 0.04p each ("Ordinary Shares") on 27 FebruaryĀ 2009, Billam AG noĀ longerĀ holdsĀ a notifiable interest in the Company.
The Company has also been informed today thatĀ on 26 and 27Ā February 2009Ā Dowgate Capital Stockbrokers sold a total of 19,068,750 Ordinary Shares and no longer has a notifiable interestĀ in the Company.
For further information:
Physiomics plc +44 (0)1865 784980
Dr Christophe Chassagnole, COOĀ
E-mail:Ā cchassagnole@physiomics-plc.com
Grant ThorntonĀ UK LLP +44 (0)20 7383 5100
Philip Secrett, Colin Aaronson
About Physiomics plc
Physiomics plc (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. As 80-90 per cent of all clinical drug candidates fail to reach the market, estimates1Ā show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million.
Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating most important molecular events taking place during the human cell cycle and apoptosis processes. Physiomics developed SystemCellĀ® technology, a multi-cellular environment software, which enables the simulation of population of "virtual cells".
Physiomics, based inĀ Oxford,Ā UK, was founded in 2001, and floated onĀ AIMĀ in 2004. For further information, please visitĀ www.physiomics-plc.com
SystemCellĀ® is a registered trademark of Physiomics plc
1Tufts Centre Impact Report 2002
Follow the stocks
